Clinical Trials on Hankittu hemofilia

Total 850 results

Pfizer

Completed

Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A

Hemophilia A

Korea, Republic of
Bayer

Completed

Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis (ReCARE)

Hemophilia A

China
University Hospital, Montpellier
Centre Hospitalier Universitaire de Saint Etienne; University Hospital, Clermont-Ferrand and other collaborators

Withdrawn

Non Neutralizing Antibodies: Prevalence and Characterization

Hemophilia A

France
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating ReFacto in Hemophilia A

Hemophilia A
Sheba Medical Center

Completed

Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII

Hemophilia A
Victor J Marder, M.D.
Baxter Healthcare Corporation

Unknown

Personalized Prediction of Tolerance and Immunogenicity in Hemophilia (PPTIH)

Hemophilia A

United States
Bayer

Completed

EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan

Hemophilia A

Taiwan
Bayer

Completed

International PMS Study - KOGENATE Bayer

Hemophilia A

Switzerland, France, Spain, Sweden, Austria, Italy, Belgium, Denmark, Greece, Netherlands
Medical University of Vienna

Completed

Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation

Hemophilia A

Austria
University of Aarhus

Completed

Clot Formation and Clot Stability in Patients With Severe Haemophilia A

Hemophilia A

Denmark
Novo Nordisk A/S

Completed

Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Spain, Germany, Japan
Novo Nordisk A/S

Completed

Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Spain
Novo Nordisk A/S

Completed

Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Investigación en Hemofilia y Fisioterapia
Real Fundación Victoria Eugenia

Completed

Functional and Proprioceptive Status in Patients With Hemophilic Ankle Arthropathy

Haemophilia

Spain
Novo Nordisk A/S

Completed

A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B (paradigm™7)

Congenital Bleeding Disorder | Haemophilia B

United States, Switzerland, Germany
Spark Therapeutics, Inc.

Recruiting

Study of a Gene Therapy Treatment for Hemophilia A (KEYSTONE 1)

Hemophilia A

United States
Radboud University Medical Center
Enzyre B.V.

Not yet recruiting

Version Testing of EnzySystem Version A for Hemophilia A

Hemophilia A

Netherlands
Xue-chun Lu

Recruiting

Combination Regimen With Sodium Valproate for Severe Hemophilia: a Single-arm, Phase 1, Pilot Trial.

Hemophilia

China
Sanofi

Recruiting

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

Hemophilia A

United States
Montefiore Medical Center
Genentech, Inc.

Not yet recruiting

Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A

Hemophilia A

United States
Emory University
Takeda Pharmaceuticals North America, Inc.

Recruiting

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis (SAFE)

Hemophilia A

United States
Washington Institute for Coagulation
Genentech, Inc.

Recruiting

Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A (EmiMSK)

Hemophilia A

United States
Emory University
Octapharma

Recruiting

Treatment of Hemophilia A Patients With FVIII Inhibitors (MOTIVATE)

Hemophilia A

United States, Germany
Sinocelltech Ltd.

Recruiting

Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.

Hemophilia A

China
Medical College of Wisconsin

Recruiting

Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A

Hemophilia A

United States
Takeda

Completed

A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions

Hemophilia

France
Bayer

Active, not recruiting

Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study) (LIFE-ACTIVE)

Hemophilia A

Canada, Spain, United States, Belgium, Italy, Taiwan, Slovenia
Hoffmann-La Roche

Active, not recruiting

Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants (HAVEN 5)

Hemophilia A

China, Thailand, Hong Kong, Malaysia
Bioverativ, a Sanofi company

Active, not recruiting

Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A (XTEND-ed)

Hemophilia A

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom
Genzyme, a Sanofi Company

Active, not recruiting

Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX (ATLAS-OLE)

Hemophilia

China, Hungary, Turkey, Canada, Korea, Republic of, United States, Australia, Denmark, France, Germany, India, Ireland, Israel, Italy, Japan, Malaysia, South Africa, Taiwan, Ukraine, United Kingdom
Haemnet
BioMarin Pharmaceutical

Completed

Learning to Live With Non-severe Haemophilia

Hemophilia

United Kingdom
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Completed

A Study of ADVATE in People With Hemophilia A in India

Hemophilia A

India
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Hemophilia

China
Hospices Civils de Lyon

Completed

Satisfaction Regarding the Dispensing of Emicizumab (HEMLIBRA®) for Patients With Haemophilia A in France (PASODOBLEDEMI2)

Hemophilia A

France
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Physical Activity and FVIII Elimination: Relevance to Personalized Therapy in Severe Hemophilia A

Hemophilia A

Italy
Swedish Orphan Biovitrum
ICON plc

Completed

Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products

Hemophilia A

France, Italy, Norway, Sweden, United Kingdom, Austria, Belgium, Finland, Spain
Genzyme, a Sanofi Company

Completed

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis (ATLAS-PPX)

Hemophilia

United States, Australia, China, Denmark, France, Ireland, Israel, Italy, Japan, Korea, Republic of, Malaysia, Turkey, Ukraine, United Kingdom, Mexico
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A (HAVEN 4)

Hemophilia A

United States, Belgium, Spain, Japan, Poland, Australia
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3)

Hemophilia A

Australia, Taiwan, Korea, Republic of, France, Germany, Italy, South Africa, Spain, United States, Japan, Ireland, Poland, United Kingdom, Costa Rica
Istanbul University - Cerrahpasa (IUC)

Completed

The Effects of Exercise Training in Children With Hemophilia

Hemophilia

Turkey
Octapharma

Completed

Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ

Hemophilia A

Norway, United States, France, United Kingdom, Italy, Czechia, Argentina, Belarus, Ecuador, Guatemala, Lithuania, Portugal, Slovakia
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Terminated

BAX 802 in CHA With Inhibitors (CHAWI)

Hemophilia A

Netherlands, Spain, Italy, Turkey, Bulgaria, United States, Canada, Germany, Norway, Poland, Russian Federation, South Africa
Baxalta now part of Shire

Completed

Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

Hemophilia A

United States
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (HAVEN 1)

Hemophilia A

Korea, Republic of, United States, France, Germany, Italy, South Africa, Spain, Japan, United Kingdom, Poland, Taiwan, Australia, Costa Rica, New Zealand
Baxalta now part of Shire

Completed

BAX 855 Pediatric Study

Hemophilia A

United States, Spain, United Kingdom, Taiwan, Malaysia, Bulgaria, Hong Kong, Korea, Republic of, Netherlands, Turkey, Ukraine
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

Hemophilia A

United States, Belgium, France, Norway, Netherlands, Austria, Hungary, Italy, Poland, Portugal, Romania, Russian Federation, Spain, Sweden
Baxalta now part of Shire

Terminated

First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients

Hemophilia

United Kingdom
Baxalta now part of Shire

Completed

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

Hemophilia A

United States, Canada, Puerto Rico
Lund University

Completed

Optimizing the Use of Prophylaxis in Patients With Severe Haemophilia A (myPKFiT)

Hemophilia A

Sweden
Baxalta now part of Shire

Completed

GAS-Hem Feasibility Study

Hemophilia A

Canada, United States

Clinical Trials on Hankittu hemofilia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations